Investor Presentation

Ref: Syn/CS/SE/IP/2026-27/Oct/08 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com October 27, 2026 To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Dear Sir/Madam, Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and half year ended September 30, 2026. The Company will use this presentation for any meeting scheduled with analysts or institutional investors. The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com. This is for your information and records. Thanking You, Yours faithfully, For SYNGENE INTERNATIONAL LIMITED Chethan Yogesh Company Secretary and Compliance Officer Enclosed: Investor Presentation Investor Presentation October 2026 Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Putting Science to Work 2 Contents Q2 FY27 Highlights Syngene – Putting Science to Work Syngene strengths Financials Shareholding and Share Information Putting Science to Work 3 Q2 FY27 Highlights Q2 FY27 performance Operating Highlights Q2 FY27 Financial Highlights • Integrated Drug Discovery (IDD):Syngene strengthened its integrated drug discovery offering Q2FY27 H1FY27 by bringing Chemistry, Biology and Biotherapeutics under unified leadership of Chief Scientific Officer Dr. Jayashree Aiyar Revenue from Rs 833 Cr Rs 1,569 Cr Operations +13% Q-o-Q -12% Y-o-Y • Bayview Biologics Facility: Syngene signed first manufacturing agreement for the Bayview -9% Y-o-Y facility with a large pharmaceutical customer – an important milestone in its large-molecule manufacturing journey. Process development is scheduled to begin in India this year, followed by drug-substance manufacturing at Bayview next year, strengthening Syngene’s integrated Operating EBITDA 18% 1 15% India-U.S. delivery model and dual-continent supply capabilities margin 12% in Q1FY27 23% in H1FY26 22% in Q2 FY26 • Biologics Manufacturing:Secured additional manufacturing contracts, including an agreement to supply clinical materials from its Bengaluru biologics facility (Unit 3). These engagements PAT, before Rs. 38 Cr Rs. 39 Cr demonstrate encouraging customer traction and support the development of a broader exceptional items2 Rs. 1 Crin Q1FY27 Rs. 154 Crin H1FY26 manufacturing pipeline Rs. 67 Crin Q2FY26 • Capability Enhancement: Commissioned a Clinical Translational Sciences laboratory in PAT, after Rs 32 Cr Rs 23 Cr Bengaluru, integrating clinical biomarker development and validation, biobanking, patient exceptional items Rs. 9 CrLoss in Q1FY27 Rs. 154 Crin H1FY26 stratification, precision medicine and bioanalytical capabilities. The facility strengthens Rs. 67 Crin Q2FY26 connectivity across discovery-development continuum. Syngene also expanded its digital capabilities through ChemVoyager, automated analytical systems and end-to-end sample tracking, enabling more connected, efficient and data-driven research workflows 1Operating EBITDA margin stood at 18%, in line with expectations, reflecting lower revenues and forex hedge losses. Adjusted for the forex hedge loss, the operating EBITDA • Cost Competitiveness: Continued implementing cost-optimization initiatives to improve margin for the quarter would be in the mid-20s range. operational efficiency and competitiveness. Manpower-related optimization has been 2 Excludes exceptional expenses related to employee termination benefits, net of tax: Rs 6 completed, while other initiatives remain underway, with benefits expected over the coming Cr for Q2 FY27 and Rs 16 Cr for H1 FY27 quarters Putting Science to Work 5 Syngene – Putting Science to Work Partner in innovation: #Putting Science to Work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more than Established track record in solutions across pharmaceuticals, biotech, ~5,700+ scientists out of total discovery research and research, development nutrition, animal health, 8,300+ headcount, operating development/ and manufacturing consumer goods and across 4 global state-of-the-art manufacturing for small specialty chemicals campuses located in India’s and large molecules leading life science hubs: Bangalore, Mangalore, Hyderabad and USA (Baltimore) Putting Science to Work 7 Our journey so far 2019 – 2026 Globalization and strategic collaboration Continued investments and growth • Expanded into formulations development • Laboratory capacity expansion in Bangalore and Hyderabad • Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules • Expansion in Mangalore for commercial API manufacturing • Extension of collaboration with BMS; • Capacity and capability addition in Biologics • Merger of Clinigene 2015 – manufacturing • Crossed annual turnover of Rs. 5 Billion 2018 • Entered in long-term partnership with Zoetis for Biologics commercial-scale manufacturing Foundation 2010 – • Acquired multi-modal biologics • Operations started IPO and further 2014 manufacturing facility from Stelis Biopharma • Expansion of R&D Lab collaborations • Granted 100% EOU status • IPO and listing • Acquired 17 acres land in Hyderabad to by the Government of India • Collaboration with support long term growth in research 2001 – Amgen to set up a business 2009 dedicated R&D center • Acquired, state of the art first biologics site Expansion in Baltimore, USA taking Syngene’s total • Expanded service offerings to single-use bioreactor capacity to 50,000L 1993 – include chemical • Invested in new capabilities and emerging 2000 development, safety modalities, such as peptides and ADCs, assessment, biologics ensuring alignment with growing global development demand • Collaboration with BMS to set up BBRC, Syngene’s first dedicated R&D Center Putting Science to Work 8 Key facts and figures ~400 16 out of top 20 400+ World class infrastructure active clients pharma companies are patents International presence with global clients held with clients campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet in [Showing first 8,000 characters — download PDF for full document]